Clinical Trials Logo

Melanoma (Skin) clinical trials

View clinical trials related to Melanoma (Skin).

Filter by:

NCT ID: NCT06439979 Recruiting - Melanoma (Skin) Clinical Trials

Rural Adult and Youth Sun Protection Study

RAYS
Start date: April 8, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to help prevent skin cancer by improving the use of sun protective behaviors among youths living in rural communities in Utah and West Virginia.

NCT ID: NCT06400550 Recruiting - Melanoma (Skin) Clinical Trials

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis

Start date: August 1, 2018
Phase:
Study type: Observational

The goal of this study is to observe metabolic features associated with human melanoma tumors.

NCT ID: NCT06377111 Not yet recruiting - Melanoma (Skin) Clinical Trials

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Start date: May 2024
Phase: Phase 1
Study type: Interventional

This study is open to patients with a type of cancer called melanoma. Patients can join the study if their tumor cannot be removed by surgery or has spread to other organs, and are planned to receive immunotherapy as treatment for their cancer. This study is looking at whether taking calcium pantothenate supplement (a type of Vitamin B5) can increase its levels in the blood and have an effect in the immune system, when its used in combination with the immunotherapy.

NCT ID: NCT06299878 Recruiting - Melanoma Stage Iii Clinical Trials

MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns]

CRISTINA
Start date: January 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about if new biomarkers such as gut microbiota and molecular genetics melanoma features could predict clinical radiological and pathological response to neoadjuvant monotherapy with anti-PD1 agents in patients with resectable stage IIIB-D melanoma. The main questions it aims to answer are: - radiological and pathological response rate to three doses of antiPD1 agents; - do radiological and pathological responses correlate with gut microbiota and melanoma molecular genetics features Participants will receive three doses of aPD1 monotherapy as per center routine practice and will undergo regional lymphadenectomy. Before treatment initiation patients will be asked to bring faeces probes and fill out dietary questionnaire as well as just before the surgery. After sugery adjuvant therapy will be prescribed for 12 month and patients will be followed up according to institutional routine practice for 5 years.

NCT ID: NCT06298734 Not yet recruiting - Melanoma (Skin) Clinical Trials

Exercise and Diet Interventions During Immunotherapy in Melanoma Patients

Start date: July 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether high-intensity exercise and high-fiber diet are feasible and improve various health outcomes among participants with advanced melanoma receiving immunotherapy. The names of the groups in this research study are: - High-Intensity Exercise (EX) - High-fiber Diet (DT) - Combined High-Intensity Exercise and High-Fiber Diet (COMB) - Attention Control (AC)

NCT ID: NCT06254547 Recruiting - Melanoma (Skin) Clinical Trials

Leaderboard Influence on Self-Regulated Training in a Gamified Dermoscopy Training App

Start date: January 27, 2024
Phase: N/A
Study type: Interventional

This study aims to examine the isolated effect of leaderboards (scoreboards) and daily training motivation on dermatology skill acquisition and training engagement within a gamified dermoscopy training platform. Research Questions: What is the effect of leaderboards and/or daily motivation on diagnostic accuracy? What is the effect of leaderboards and/or daily motivation on self-regulated learning: time spent training and case amount? What is the effect of leaderboards and/or daily motivation on training distribution? Method: 150 danish medical students will upon inclusion and end of trial answer a Multiple Choice Questionnaire (MCQ). Participants will be asked to download the gamified training platform onto their mobile devices. Within the app participants can access quizzes on a library of 10,000+ skin lesions combined with written educational modules on histopathological skin diagnosis. Participants receive instant feedback on quiz answered. Points are awarded for correct answers and removed for incorrect answers. Participants will be randomized to one of three groups; either receiving no communication from the principal investigator, receiving a daily motivational message, or receiving a once daily updated leaderboard ranking participant's scores. The intervention will last for seven days, followed by a 14-day washout period.

NCT ID: NCT06221397 Recruiting - Melanoma Clinical Trials

Clinical Validation Study of an AI-based CAD System for Early Non-Invasive Detection of Cutaneous Melanoma

LEGIT_MC_EVCDA
Start date: September 17, 2020
Phase:
Study type: Observational [Patient Registry]

The goal of this Cross-sectional analytical observational study of clinical case series is to validate a Computer-aided diagnosis software developed by AI Labs Group for the identification of cutaneous melanoma in images of lesions taken with a dermatoscopic camera. This study will be carried out in patients with skin lesions with suspected malignancy seen at the Dermatology Department of the Cruces University Hospital and Basurto University Hospital. The main questions it aims to answer are: - If the AI algorithm developed by AI Labs group is a valid tool to identify cutaneous melanoma in dermoscopic images with high reliability. - Comparing the device's performance with dermatologists, with primary care physicians' assessment to be considered in later phases. - Assessing the utility and feasibility of the device in adverse environments with technical limitations. In this way, patients with skin lesions with suspected malignancy seen at the Dermatology Department of the Cruces and Basurto University Hospitals will be recruited. Patients in this study will not receive any specific treatment as part of the research protocol. In addition, they will continue their regular prescribed medications and treatments as directed by their primary healthcare providers. This study does not require doing a follow-up of the subjects. Every patient only gets their skin lesions photographed at the time of visit.

NCT ID: NCT05990634 Active, not recruiting - Melanoma (Skin) Clinical Trials

LifeChamps Feasibility Study

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to collect data from various sources (PROM / PREM, sensors, journal data) to train AI based models in the LifeChamps digital platform in a pre-pilot, as well as partly implement a pilot/feasibility study to examine the applicability of the digital technology developed in LifeChamps, as well as the usability for patients (cancer survivors) and health care professionals

NCT ID: NCT05986331 Active, not recruiting - Melanoma (Skin) Clinical Trials

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Start date: July 18, 2022
Phase: Phase 3
Study type: Interventional

This clinical study is designed as a randomized, double-blind trial. Subjects with unresectable, metastatic, or recurrent skin melanoma will be randomized to one of the two study groups (BCD-201 group and Keytruda group) at a 1:1 ratio. The goal of this study is to compare the efficacy and safety of BCD-201 and Keytruda as first-line therapy in subjects with unresectable, metastatic, or recurrent skin melanoma.

NCT ID: NCT05982600 Enrolling by invitation - Melanoma (Skin) Clinical Trials

Safety and Avoidance of Futile Excisions Through Skin Tele-triage

SAFEST
Start date: March 1, 2024
Phase:
Study type: Observational

The goal of this study is to estimate the triage values, efficiency and safety of tele-dermoscopic triage of skin lesions suspected of melanoma. The main question[s] it aims to answer are: - What is the rate of correct patient management by a single, 2, 3 and 5 dermatologists. - What is the consequence for the patients if teledermoscopic triage is implemented, in termes of missed melanomas and reduced unnecessary excisions/biopsies. Retrospectively included patients will have their skin lesions re-examined by setups of 1, 2, 3 and 5 tele-dermoscopists who will assign a tentative diagnosis and a recommended clinical action. The investigators will compare the rate of correct patient management between the different setups.